

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

PE anti-mouse CD80

RRID:AB_313129

Type: Antibody

Proper Citation

BioLegend Cat# 104708, RRID:AB_313129

Antibody Information

URL: http://antibodyregistry.org/AB_313129

Proper Citation: BioLegend Cat# 104708, RRID:AB_313129

Target Antigen: CD80

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD80

Description: This monoclonal targets CD80

Target Organism: mouse

Clone ID: Clone 16-10A1

Antibody ID: AB_313129

Vendor: BioLegend

Catalog Number: 104708

Alternative Catalog Numbers: 104707

Record Creation Time: 20250819T231002+0000

Record Last Update: 20250820T042957+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD80.

No alerts have been found for PE anti-mouse CD80.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. *Cell reports. Medicine*, 102532.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. *Molecular cancer therapeutics*, 24(6), 843.

Xue F, et al. (2025) Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine. *iScience*, 28(4), 112120.

Wang Z, et al. (2025) Tumor microenvironment-associated oxidative stress impairs SIRT1 secretion to suppress anti-tumor immune response. *Cell reports*, 44(5), 115679.

Qu K, et al. (2025) Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice. *International immunopharmacology*, 167, 115648.

Shi T, et al. (2025) CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. *Cancer cell*.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOA as a potential immunotherapy. *Cell*, 188(18), 5062.

Lin SH, et al. (2025) Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. *Med (New York, N.Y.)*, 100752.

Wu F, et al. (2025) Generating structurally and functionally programmable hydrogels by biological membrane hybridization. *Nature protocols*.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. *Cell reports*, 43(4), 114041.

Wakamatsu E, et al. (2024) Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II. *Cell reports*, 43(9), 114655.

Gräbnitz F, et al. (2023) Asymmetric cell division safeguards memory CD8 T cell development. *Cell reports*, 42(5), 112468.

Glaros V, et al. (2021) Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response. *Immunity*, 54(9), 2005.

Lightman SM, et al. (2021) Indoleamine 2,3-dioxygenase 1 is essential for sustaining durable antibody responses. *Immunity*, 54(12), 2772.

Tsukasaki M, et al. (2020) OPG Production Matters Where It Happened. *Cell reports*, 32(10), 108124.

Wong R, et al. (2020) Affinity-Restricted Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses. *Immunity*, 53(5), 1078.

Chagwedera DN, et al. (2019) Nutrient Sensing in CD11c Cells Alters the Gut Microbiota to Regulate Food Intake and Body Mass. *Cell metabolism*, 30(2), 364.

Koyama M, et al. (2019) MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. *Immunity*, 51(5), 885.

Ding L, et al. (2018) PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. *Cell reports*, 25(11), 2972.